1012 related articles for article (PubMed ID: 23786573)
1. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
[TBL] [Abstract][Full Text] [Related]
4. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
[TBL] [Abstract][Full Text] [Related]
6. [Micafungin in invasive candidiasis among oncohematological patients].
Jarque I; Angel Sanz M
Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
11. Outcomes by
Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
[TBL] [Abstract][Full Text] [Related]
12. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
13. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
14. Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution.
Liew YX; Teo J; Too IA; Ngan CC; Tan AL; Chlebicki MP; Kwa AL; Lee W
BMC Infect Dis; 2015 Jul; 15():256. PubMed ID: 26137997
[TBL] [Abstract][Full Text] [Related]
15. Echinocandin use in the neonatal intensive care unit.
Caudle KE; Inger AG; Butler DR; Rogers PD
Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
17. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
Kuse ER; Chetchotisakd P; da Cunha CA; Ruhnke M; Barrios C; Raghunadharao D; Sekhon JS; Freire A; Ramasubramanian V; Demeyer I; Nucci M; Leelarasamee A; Jacobs F; Decruyenaere J; Pittet D; Ullmann AJ; Ostrosky-Zeichner L; Lortholary O; Koblinger S; Diekmann-Berndt H; Cornely OA;
Lancet; 2007 May; 369(9572):1519-1527. PubMed ID: 17482982
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Wang H; Xu YC; Hsueh PR
Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
